Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester manufacturers
- JQ1-TCO
-
-
2025-06-07
- CAS:2087490-43-3
- Min. Order: 1mg
- Purity: >95.00%
- Supply Ability: 1mg
|
| | Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester Basic information |
| Product Name: | Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester | | Synonyms: | Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester | | CAS: | 2087490-43-3 | | MF: | C31H37ClN6O3S | | MW: | 609.18 | | EINECS: | | | Product Categories: | | | Mol File: | 2087490-43-3.mol | ![Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester Structure](CAS/20210305/GIF/2087490-43-3.gif) |
| | Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | pka | 12.41±0.46(Predicted) | | form | Solid | | color | White to light yellow |
| | Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester Usage And Synthesis |
| Uses | JQ1-TCO (JQ1-trans-cyclooctene) is a derivative of JQ1 (HY-13030), an inhibitor of BET. JQ1-TCO is suitable for click chemistry and can be used as molecular probes in vitro and in vivo[1][2]. | | IC 50 | BRD4 | | References | [1] Hu Z, et al. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic. Chembiochem. 2022 Jan 19;23(2):e202100270. DOI:10.1002/cbic.202100270 [2] Tyler DS, et al. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. Science. 2017 Jun 30;356(6345):1397-1401. DOI:10.1126/science.aal2066 |
| | Carbamic acid, N-[3-[[2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetyl]amino]propyl]-, 4-cycloocten-1-yl ester Preparation Products And Raw materials |
|